...heterosexual transmission of the virus and developing the Walter Reed staging system for HIV infection. Mary Romeo Profectus BioSciences Inc. University...

...has ALVAC-HIV (vCP2438), a canarypox vector-based vaccine, in Phase II/III testing to prevent HIV-1 infection. Profectus BioSciences Inc....

...as executive medical director. Lynch also is chairman of Evofem Inc. (San Diego, Calif.) and Profectus BioSciences Inc....

...advanced cancer. The companies will use Vyriad’s recombinant vesicular stomatitis virus (rVSV)-derived oncolytic viruses and Profectus’...
...they expect clinical trials to begin in 2017. The companies declined to disclose financial terms. Profectus BioSciences Inc....

...dose-escalation, U.S. Phase I trial to evaluate intramuscular VesiculoVax-vectored Ebola virus vaccine in 39 subjects. Profectus BioSciences Inc....

...have RVSV-EBOV (rVSV-EBOV; rVSV-ZEBOV-GP ; VSV-EBOV ; VSV-ZEBOV ; BPSC1001 ) in Phase II/III testing. Profectus BioSciences Inc....

...In rhesus macaques, a single dose of Profectus’ VesiculoVax Ebola vaccine given 28 days prior to...
...vaccine engineered to express the surface protein from the Zaire variant of the Ebola virus. Profectus BioSciences Inc....

...vaccines from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK, London, U.K.), NewLink Genetics Corp. (NASDAQ:NLNK, Ames, Iowa) and Profectus BioSciences Inc....

...Diego, Calif.), and Ebola vaccines from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), NewLink Genetics Corp. (NASDAQ:NLNK) and Profectus BioSciences Inc....

...formulation of ALVAC HIV vaccine; (D) With assistance from NIAID, the Gates Foundation and MHRP, Profectus Biosciences Inc....
...an antibody response and Ad4-mGag to induce a broadly reactive T cell response Ph I Profectus Biosciences Inc....
...Profectus Biosciences Inc. (D) VesiculoVax HIV vaccine (A) rVSV expressing envelope protein of HIV clade C Preclin Profectus BioSciences Inc....